137 related articles for article (PubMed ID: 36229265)
1. Genomic profiling in low grade serous ovarian cancer: Identification of novel markers for disease diagnosis and therapy.
ElNaggar A; Robins D; Baca Y; Arguello D; Ulm M; Arend R; Mantia-Smaldone G; Chu C; Winer I; Holloway R; Krivak T; Jones N; Galvan-Turner V; Herzog TJ; Brown J
Gynecol Oncol; 2022 Nov; 167(2):306-313. PubMed ID: 36229265
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic and Molecular Features of Paired Cases of Metachronous Ovarian Serous Borderline Tumor and Subsequent Serous Carcinoma.
Chui MH; Xing D; Zeppernick F; Wang ZQ; Hannibal CG; Frederiksen K; Kjaer SK; Cope L; Kurman RJ; Shih IM; Wang TL; Vang R
Am J Surg Pathol; 2019 Nov; 43(11):1462-1472. PubMed ID: 31343420
[TBL] [Abstract][Full Text] [Related]
3. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.
Della Pepa C; Tonini G; Santini D; Losito S; Pisano C; Di Napoli M; Cecere SC; Gargiulo P; Pignata S
Cancer Treat Rev; 2015 Feb; 41(2):136-43. PubMed ID: 25573350
[TBL] [Abstract][Full Text] [Related]
4. KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.
Tsang YT; Deavers MT; Sun CC; Kwan SY; Kuo E; Malpica A; Mok SC; Gershenson DM; Wong KK
J Pathol; 2013 Dec; 231(4):449-56. PubMed ID: 24549645
[TBL] [Abstract][Full Text] [Related]
5. Molecular diagnosis in type I epithelial ovarian cancer.
Sadłecki P; Walentowicz-Sadłecka M; Grabiec M
Ginekol Pol; 2017; 88(12):692-697. PubMed ID: 29303228
[TBL] [Abstract][Full Text] [Related]
6. Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR.
Bösmüller H; Fischer A; Pham DL; Fehm T; Capper D; von Deimling A; Bonzheim I; Staebler A; Fend F
Hum Pathol; 2013 Mar; 44(3):329-35. PubMed ID: 23089489
[TBL] [Abstract][Full Text] [Related]
7. Somatic Genomic and Transcriptomic Characterization of Primary Ovarian Serous Borderline Tumors and Low-Grade Serous Carcinomas.
Stružinská I; Hájková N; Hojný J; Krkavcová E; Michálková R; Bui QH; Matěj R; Laco J; Drozenová J; Fabian P; Škapa P; Špůrková Z; Cibula D; Frühauf F; Jirásek T; Zima T; Méhes G; Kendall Bártů M; Němejcová K; Dundr P
J Mol Diagn; 2024 Apr; 26(4):257-266. PubMed ID: 38280423
[TBL] [Abstract][Full Text] [Related]
8. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathologic, Immunohistochemical, and Molecular Characteristics of Ovarian Serous Carcinoma With Mixed Morphologic Features of High-grade and Low-grade Serous Carcinoma.
Zarei S; Wang Y; Jenkins SM; Voss JS; Kerr SE; Bell DA
Am J Surg Pathol; 2020 Mar; 44(3):316-328. PubMed ID: 31876585
[TBL] [Abstract][Full Text] [Related]
10. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.
Hsu CY; Bristow R; Cha MS; Wang BG; Ho CL; Kurman RJ; Wang TL; Shih IeM
Clin Cancer Res; 2004 Oct; 10(19):6432-6. PubMed ID: 15475429
[TBL] [Abstract][Full Text] [Related]
11. Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation.
Combe P; Chauvenet L; Lefrère-Belda MA; Blons H; Rousseau C; Oudard S; Pujade-Lauraine E
Invest New Drugs; 2015 Dec; 33(6):1267-70. PubMed ID: 26490654
[TBL] [Abstract][Full Text] [Related]
12. The molecular pathology of ovarian serous borderline tumors.
Malpica A; Wong KK
Ann Oncol; 2016 Apr; 27 Suppl 1(Suppl 1):i16-i19. PubMed ID: 27141064
[TBL] [Abstract][Full Text] [Related]
13. Molecular characterization of 103 ovarian serous and mucinous tumors.
Vereczkey I; Serester O; Dobos J; Gallai M; Szakács O; Szentirmay Z; Tóth E
Pathol Oncol Res; 2011 Sep; 17(3):551-9. PubMed ID: 21136228
[TBL] [Abstract][Full Text] [Related]
14. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems.
Vang R; Shih IeM; Kurman RJ
Adv Anat Pathol; 2009 Sep; 16(5):267-82. PubMed ID: 19700937
[TBL] [Abstract][Full Text] [Related]
15. Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes.
Hunter SM; Anglesio MS; Ryland GL; Sharma R; Chiew YE; Rowley SM; Doyle MA; Li J; Gilks CB; Moss P; Allan PE; Stephens AN; Huntsman DG; deFazio A; Bowtell DD; ; Gorringe KL; Campbell IG
Oncotarget; 2015 Nov; 6(35):37663-77. PubMed ID: 26506417
[TBL] [Abstract][Full Text] [Related]
16. Low-grade serous ovarian cancer: A review.
Kaldawy A; Segev Y; Lavie O; Auslender R; Sopik V; Narod SA
Gynecol Oncol; 2016 Nov; 143(2):433-438. PubMed ID: 27581327
[TBL] [Abstract][Full Text] [Related]
17. Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants.
Ardighieri L; Zeppernick F; Hannibal CG; Vang R; Cope L; Junge J; Kjaer SK; Kurman RJ; Shih IeM
J Pathol; 2014 Jan; 232(1):16-22. PubMed ID: 24307542
[TBL] [Abstract][Full Text] [Related]
18. Association of Anti-EGFR Antibody and MEK Inhibitor in Gynecological Cancer Harboring RAS Mutation: A Case Series.
Niogret J; Derangère V; Richard C; Nuttin L; Ghiringhelli F; Favier L; Lefevre LB; Bergeron A; Arnould L; Boidot R
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328764
[TBL] [Abstract][Full Text] [Related]
19. Expression of BRAF V600E mutant protein in epithelial ovarian tumors.
Preusser M; Capper D; Berghoff AS; Horvat R; Wrba F; Schindl M; Schoppmann SF; von Deimling A; Birner P
Appl Immunohistochem Mol Morphol; 2013 Mar; 21(2):159-64. PubMed ID: 22820660
[TBL] [Abstract][Full Text] [Related]
20. Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas.
Tone AA; McConechy MK; Yang W; Ding J; Yip S; Kong E; Wong KK; Gershenson DM; Mackay H; Shah S; Gilks B; Tinker AV; Clarke B; McAlpine JN; Huntsman D
BMC Cancer; 2014 Dec; 14():982. PubMed ID: 25523272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]